Transcode Therapeutics Has Dosed All Patients In The First Cohort Of Its Phase 1A Dose-escalation Clinical Trial Of TTX-MC138, Which Is Designed To Inhibit MicroRNA-10b, MicroRNA Critical To The Emergence And Progression Of Metastatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Transcode Therapeutics has successfully dosed all patients in the first cohort of its Phase 1A clinical trial for TTX-MC138, targeting microRNA-10b in metastatic cancer. No significant safety issues have been reported.
October 10, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Transcode Therapeutics has dosed all patients in the first cohort of its Phase 1A trial for TTX-MC138, with no significant safety issues reported. This is a positive development in their cancer treatment research.
The successful dosing of all patients in the first cohort without significant safety issues is a positive indicator for the progress of Transcode Therapeutics' clinical trial. This could lead to increased investor confidence and a potential short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100